Skip to content
Screener

Integra LifeSciences IART ENT — Total Revenues

Discontinued — last reported Q1 '26

Other product segments

Neurosurgery
$213.26M+2.0%
Wound Reconstruction
$79.65M+6.5%
Instruments
$47.23M-7.3%
Private Label
$28.19M+4.8%

Similar metrics at other companies

ESP
ESPRCollaboration revenue — Total Revenues
$36.71M+22.0%
CME Group logo
CMEOther Revenue — Total Revenues
$115.6M+9.2%
AMR
AMRZInterproduct revenues — Total Revenues
-$151M-3.4%
ESP
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%
Riley Exploration Permian logo
REPXNGL sales, net — Total Revenues
-$3.04M-976%
Riley Exploration Permian logo
REPXOil sales, net — Total Revenues
$182.25M+112%

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.33B+38.0%
Enterprise value$3.08B+16.2%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%—
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%—
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Integra LifeSciences’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000917520-26-000041
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Neurosurgery$198,195$190,912
Instruments47,23350,950
ENT37,70738,802
Total Specialty Surgery283,135280,664
Wound Reconstruction79,64874,779
Private Label29,13527,210
Total Tissue Reconstruction108,783101,989
Total Revenue$391,918$382,653

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's ENT — total revenues?
Integra LifeSciences (IART) reported ENT — total revenues of $37.71M in Q1 2026.
How has Integra LifeSciences's ENT — total revenues changed year-over-year?
Integra LifeSciences's ENT — total revenues decreased by 2.8% year-over-year, from $38.8M to $37.71M.
What is the long-term trend for Integra LifeSciences's ENT — total revenues?
Over 3 years (2022 to 2025), Integra LifeSciences's ENT — total revenues has grown at a 71.7% compound annual growth rate (CAGR), from $32.87M to $166.37M.
What does ENT — total revenues mean?
This metric represents the total net revenue generated by the Ear, Nose, and Throat (ENT) product segment. It reflects the market demand and commercial performance of specialized medical devices and solutions tailored for otolaryngology applications. Tracking this revenue stream allows investors to evaluate the growth trajectory and competitive positioning of the company's ENT portfolio within the broader medical technology market.

Ask your AI about Integra LifeSciences's ent — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude